Metastatic Spinal Bone Marrow Response to Radiation Therapy Using T1 Weighted Dynamic Contrast-Enhanced Perfusion

Evaluation of Metastatic Spinal Bone Marrow Response to Radiation Therapy Using T1 Weighted Dynamic Contrast-Enhanced Perfusion

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02376127

Enrollment

Registered

2015-03-03

Start date

2015-02-24

Completion date

2025-07-16

Last updated

2025-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Spinal Lesions, Solid Cancer

Keywords

Dynamic Contrast-Enhanced Perfusion, 14-203

Brief summary

The purpose of this study is to assess imaging methods including Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) and perfusion for the cancer that has spread to the spine. The study aims to see if using these methods will help better see response to treatment with radiation in patients with spine metastases from any solid cancer.

Interventions

PROCEDUREDynamic contrast enhancement MRI

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients 18 years of age or older * Known pathological diagnosis of any solid cancer. * Metastatic spinal lesions 1 cm or greater in diameter. * Patients who are already eligible for and are to be treated with hypofractionated or single dose radiation for their spinal lesions. Note: The patients must have their treatments at MSKCC.

Exclusion criteria

* Patients with renal failure or history of allergic reaction to Gadavist will be excluded. * Patients who would be normally excluded from undergoing an MRI examination as per Memorial Hospital for Cancer and Allied Disease Screening Questionnaire for MRI. * Patients with a pacemaker, aneurysm clip or any other condition that would warrant avoidance of a strong magnetic field. * Patients with inability to cooperate for an MRI exam due to claustrophobia or high levels of anxiety. * Female patients who are pregnant or nursing. * Patients with eGFR \< 30 are not eligible to higher risk of NSF.

Design outcomes

Primary

Measure	Time frame	Description
response to treatment	2 years	will be based on clinical assessment and conventional MRI and PET imaging, evaluating images for evidence of tumor contraction and stable disease for more than 11 months. Clinical assessment is done by radiation oncology and is based on physical examination, patient symptoms and consideration of radiological studies.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026